Navigation Links
2009 is Healthy for Asia
Date:1/13/2009

Diverse impacts in the healthcare industry creates growth opportunities for healthcare and life science companies in the region

SINGAPORE, Jan. 13 /PRNewswire/ -- The credit crisis and the global economy meltdown has contributed to a significant shift in the Healthcare industry in 2009. Healthcare in Asia Pacific will not be affected as severely as the developed countries.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

Dr. Louis Payet, Senior Consultant of the Healthcare Practice, Asia Pacific at Frost & Sullivan says that Asia will also benefit from this crisis as healthcare companies in the US and EU come under significant cost pressure.

"Healthcare Indices, while declining, have still outperformed the broader market. This implies that investors are still expecting positive activities within the industry in this region," says Dr. Payet.

He further adds that as countries like Japan and Singapore are already in recessions and most other regional economies are slowing, the healthcare market is still experiencing positive growth.

He also added that the governments are also responding to the crisis by trying to stimulate economic activity through alleviation of lack of liquidity and then injecting further stimulated growth via interest rate cuts and increased government spending.

Dr. Payet on a separate note cautions that the symptoms of the downturn should not be taken lightly. While the cost of debt may fall in 2009 it is anticipated that accessing debt will continue to be challenging.

"Pharmaceutical and medtech companies should be better positioned to deal with this situation than other healthcare groups. These companies typically have stronger cash flows and a lower reliance on debt funding. This creates opportunities for expansion and acquisition," comments Dr. Payet.

Are healthcare companies going to suffer their losses as the consumer discretionary spending decline?

According to Dr. Payet, the healthcare industry is perceived more as a defensive in comparison to other industries. More often products are viewed as essential goods that should be less affected by cyclical economic events.

Mr Simranjit Singh, Associate Director of the Healthcare Practice, Asia Pacific at Frost & Sullivan estimates the Asian Healthcare market in 2008 to be valued at about US $240 billion with the largest contributor being the Pharmaceuticals at 66.2 percent followed by the Medical Devices at 21.2 percent, Biotechnology at 6.7 percent, Clinical Diagnostics & Healthcare IT at 2.1 percent & Medical Imaging at 1.5 percent. In 2009, the Asian Healthcare Market is expected to grow by 5 to 10 percent.

"Due to the greater healthcare costs pressures, 2009 will also see the paradigm shift in healthcare spend in Asia from being treatment centric to move towards the 3 P's of healthcare - Predictive, Personalised & Preventative healthcare," comments Mr Singh.

Mr Singh further elaborates that the financial crisis presents an array of opportunities to key players in the healthcare industry especially Pharma & Medical technology companies. In a recent interview the CEO of Merck, Mr Richard Clark, highlighted that one of the key goals of Merck in 2009 was to look at distressed biotech companies that would be able boost Merck's revenue and beef up its pipeline.

Several Medtech companies like Philips Medical & GE Healthcare are looking for growth opportunities in emerging markets and they have taken bold steps with acquisitions or JVs with niche Medtech players in China & India such as Meditronics, Alpha X-ray & Shinva.

2009 represents an opportunity for Asia to takeover the mantle of leadership from the US & Europe to become the key driver of innovation and profitability for Healthcare companies.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

    Contact:
    Jasminder Kaur
    Corporate Communications - Healthcare, Asia Pacific
    DID: +65 6890 0937
    Mobile: +65 9062 7051
    Email: jkaur@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
2. HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City
3. Immureboost Inc Announces a Change of Name to Fountain Healthy Aging Inc
4. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
5. Isabellas Healthy Bakery Unveils Activate - A New Probiotic Muffin Fortified with GanedenBC30 Probiotic
6. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
7. A Scientist Dechipers the Code to Beautiful, Healthy Skin in The New Science of Perfect Skin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... oncology and dermatology biopharmaceutical company, today is providing ... its previously announced rights offering of up to ... stock and Series C Convertible Preferred Stock to ... As previously announced, the rights offering ...
(Date:2/24/2017)... ... February 24, 2017 , ... FireflySci, Inc is an explosive ... 2014, FireflySci had the goal of bringing their powerful cuvette and spectrophotometer ... the path that FireflySci is going on as they add yet another mark on ...
(Date:2/23/2017)... Financial Highlights (in ... Months Ended December 31,Twelve Months Ended December 31,20162015% ... $           300$     ... Revenue 3539(10)%9498(4)%Kuvan Net Product Revenue ... 756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... , Feb. 23, 2017  Seattle,s upscale Capitol Hill neighborhood, ... strange place for a head lice treatment salon to set ... a Tuscan restaurant and a French bistro on E Madison ... "We aren,t just any old lice clinic, we pride ourselves ... comfortable, and release some of the stigma associated with lice. ...
Breaking Biology Technology:
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
(Date:2/2/2017)... 1, 2017  Central to its deep commitment ... worldwide, The Japan Prize Foundation today announced the ... pushed the envelope in their respective fields of ... scientists are being recognized with the 2017 Japan ... only contribute to the advancement of science and ...
(Date:1/31/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company ... of bacterial infections, today announced it has acquired ... Pro Bono Bio Ltd (PBB) to bolster its ... forms of Gram-negative bacteria.   The assets acquired have ... PBB group company. "The acquisition of ...
Breaking Biology News(10 mins):